Bronchiectasis in non cystic fibrosis patients
Transcript of Bronchiectasis in non cystic fibrosis patients
![Page 1: Bronchiectasis in non cystic fibrosis patients](https://reader030.fdocuments.net/reader030/viewer/2022020620/61e581c46059ad0d07778e8b/html5/thumbnails/1.jpg)
Bronchiectasis in non cystic fibrosis patients
Francesco Blasi
Department of Pathophysiology and Transplantation
University of Milan
![Page 2: Bronchiectasis in non cystic fibrosis patients](https://reader030.fdocuments.net/reader030/viewer/2022020620/61e581c46059ad0d07778e8b/html5/thumbnails/2.jpg)
Recurrent cough, sputum and respiratory infections
Common- reported prevalence of 52/100,000
Failed bacterial clearance with chronic bacterial colonisation and neutrophilic airway inflammation
The cause is unknown in >60% of cases
No licensed therapies- Historically neglected
Bronchiectasis
![Page 3: Bronchiectasis in non cystic fibrosis patients](https://reader030.fdocuments.net/reader030/viewer/2022020620/61e581c46059ad0d07778e8b/html5/thumbnails/3.jpg)
Neutrophils: Proinflammatory cytokinesProteases (elastase, cathepsins,MMP’s)Macrophages: Proinflammatory cytokinesFailed clearance of apoptotic cellsEpithelial cells: IL-8, TNF-alpha secretion
Primary host defences Secondary host defences
Fuschillo ERJ 2008
![Page 4: Bronchiectasis in non cystic fibrosis patients](https://reader030.fdocuments.net/reader030/viewer/2022020620/61e581c46059ad0d07778e8b/html5/thumbnails/4.jpg)
Aetiology
![Page 5: Bronchiectasis in non cystic fibrosis patients](https://reader030.fdocuments.net/reader030/viewer/2022020620/61e581c46059ad0d07778e8b/html5/thumbnails/5.jpg)
Why should COPD experts and researchers care about bronchiectasis?
N=2164Bronchiectasis5% GOLD III, 7% GOLD IV
N=3636Bronchiectasis20.8%- associated with more exacerbations, worse FEV1
Single centre studies-50-60% of patients with moderate to severe COPD-More bacterial colonisation-More P. aeruginosa-Independent predictor of death
Stewart et al, AJRCCM 2012Agusti et al, Respir Res 2012Martinez et al AJRCCM 2013Getheral et al COPD 2014
![Page 6: Bronchiectasis in non cystic fibrosis patients](https://reader030.fdocuments.net/reader030/viewer/2022020620/61e581c46059ad0d07778e8b/html5/thumbnails/6.jpg)
Why should bronchiectasis experts and researchers care about COPD?
750 million people in Europe
5-10% have COPD
5-50% of these have bronchiectasis
A conservative estimate suggests at least 1m people in Europe have COPD associated bronchiectasis
![Page 7: Bronchiectasis in non cystic fibrosis patients](https://reader030.fdocuments.net/reader030/viewer/2022020620/61e581c46059ad0d07778e8b/html5/thumbnails/7.jpg)
Idiopathic -Lower lobe disease-Good prognosis-60 year old females
ABPA-Central disease-History of asthma-Staphylococcus aureus colonisation
Non tuberculous Mycobacteria-Middle age females-Middle lobe disease-Possible genetic/morphological associations
COPD-Bilateral lower lobe cylindrical bronchiectasis-Chronic bronchitis-Severe disease and poor prognosis
Cystic fibrosis-Upper lobe disease-Colonisation with S.aureus/P. aeruginosa-Early onset
Phenotypes
![Page 8: Bronchiectasis in non cystic fibrosis patients](https://reader030.fdocuments.net/reader030/viewer/2022020620/61e581c46059ad0d07778e8b/html5/thumbnails/8.jpg)
Non-CF Bronchiectasis OR Non-COPD bronchiectasis?
Disease predominantly affecting the middle age and elderly
Typically associated with airflow obstruction
Colonisation with H. influenzae and M. catarrhalis
P. aeruginosa in severe disease
Neutrophil dominated airway inflammation
COPD Bronchiectasis
Defined by fixed airflow obstruction Defined by Radiology
Inhaled corticosteroids
Bronchodilators
PDE4 inhibitors
Macrolides
Inhaled antibiotics
Mucoactive therapies
![Page 9: Bronchiectasis in non cystic fibrosis patients](https://reader030.fdocuments.net/reader030/viewer/2022020620/61e581c46059ad0d07778e8b/html5/thumbnails/9.jpg)
What bronchiectasis can learn from COPD
• Large scale epidemiological studies
• Severity classification
• Phenotyping of patients
• Recognition of the importance of co-morbidities
• Large scale randomized controlled trials and collaboration with pharmaceutical industry
![Page 10: Bronchiectasis in non cystic fibrosis patients](https://reader030.fdocuments.net/reader030/viewer/2022020620/61e581c46059ad0d07778e8b/html5/thumbnails/10.jpg)
What is EMBARC?
A pan-European collaborative network to promote research in bronchiectasis
Funded and supported by the European Respiratory Society as a clinical research collaboration
An alliance between national networks, expert centres and investigator
Open to everyone
![Page 11: Bronchiectasis in non cystic fibrosis patients](https://reader030.fdocuments.net/reader030/viewer/2022020620/61e581c46059ad0d07778e8b/html5/thumbnails/11.jpg)
International bronchiectasis networks
![Page 12: Bronchiectasis in non cystic fibrosis patients](https://reader030.fdocuments.net/reader030/viewer/2022020620/61e581c46059ad0d07778e8b/html5/thumbnails/12.jpg)
![Page 13: Bronchiectasis in non cystic fibrosis patients](https://reader030.fdocuments.net/reader030/viewer/2022020620/61e581c46059ad0d07778e8b/html5/thumbnails/13.jpg)
![Page 14: Bronchiectasis in non cystic fibrosis patients](https://reader030.fdocuments.net/reader030/viewer/2022020620/61e581c46059ad0d07778e8b/html5/thumbnails/14.jpg)
Members from 35 countries
212 registered centres
![Page 15: Bronchiectasis in non cystic fibrosis patients](https://reader030.fdocuments.net/reader030/viewer/2022020620/61e581c46059ad0d07778e8b/html5/thumbnails/15.jpg)
EMBARC registry
![Page 16: Bronchiectasis in non cystic fibrosis patients](https://reader030.fdocuments.net/reader030/viewer/2022020620/61e581c46059ad0d07778e8b/html5/thumbnails/16.jpg)
EMBARCThe European Bronchiectasis Registry.
![Page 17: Bronchiectasis in non cystic fibrosis patients](https://reader030.fdocuments.net/reader030/viewer/2022020620/61e581c46059ad0d07778e8b/html5/thumbnails/17.jpg)
![Page 18: Bronchiectasis in non cystic fibrosis patients](https://reader030.fdocuments.net/reader030/viewer/2022020620/61e581c46059ad0d07778e8b/html5/thumbnails/18.jpg)
![Page 19: Bronchiectasis in non cystic fibrosis patients](https://reader030.fdocuments.net/reader030/viewer/2022020620/61e581c46059ad0d07778e8b/html5/thumbnails/19.jpg)
What can we achieve with a European Bronchiectasis Registry?
![Page 20: Bronchiectasis in non cystic fibrosis patients](https://reader030.fdocuments.net/reader030/viewer/2022020620/61e581c46059ad0d07778e8b/html5/thumbnails/20.jpg)
Data from 1310 patients in 4 countriesThe first validated prediction rule for bronchiectasis
![Page 21: Bronchiectasis in non cystic fibrosis patients](https://reader030.fdocuments.net/reader030/viewer/2022020620/61e581c46059ad0d07778e8b/html5/thumbnails/21.jpg)
DundeeEdinburgh
Newcastle
Leuven
Milan
5 European Centres•Dundee•Edinburgh•Leuven•Milan•Newcastle
Total study population 1310
EdinburghDerivation
Validation
Dundee
Leuven
Milan
Newcastle
![Page 22: Bronchiectasis in non cystic fibrosis patients](https://reader030.fdocuments.net/reader030/viewer/2022020620/61e581c46059ad0d07778e8b/html5/thumbnails/22.jpg)
Components of the BSIAge Points<50 050-69 270-79 480+ 6
BMI Points<18.5 2>18.5 0
FEV1% pred. Points>80% 050-80% 130-49% 2<30% 3
Hospital adm. PointsYes 5No 0
Exacerbation frequency Points3 or more per year 2<3 per year 0
MRC dyspnoea score Points1-3 04 25 3
Colonisation status PointsNo 0Colonised 1P. aeruginosa 3
Radiology Points3 or more lobes or 1 cystic changes<3 lobes involved 0
Classification of the BSIMild = 0-4 Severe = 9+Moderate = 4-8 (Range = 0-25)
![Page 23: Bronchiectasis in non cystic fibrosis patients](https://reader030.fdocuments.net/reader030/viewer/2022020620/61e581c46059ad0d07778e8b/html5/thumbnails/23.jpg)
![Page 24: Bronchiectasis in non cystic fibrosis patients](https://reader030.fdocuments.net/reader030/viewer/2022020620/61e581c46059ad0d07778e8b/html5/thumbnails/24.jpg)
www.bronchiectasisseverity.com
![Page 25: Bronchiectasis in non cystic fibrosis patients](https://reader030.fdocuments.net/reader030/viewer/2022020620/61e581c46059ad0d07778e8b/html5/thumbnails/25.jpg)
Use of the Bronchiectasis Severity Index for discovery science
Mild severe
1. PCA scores plot indicates that sputum protein profiles are associated with disease severity2. Patients 2, 10, 16, 17 18, 29 and 44 clustered with the majority of severe patients- potentially higher priority
for therapeutic treatments. 3. Conversely patients 11, 12 and 41 are closer to the majority of mild patients, thus potentially no need for
active treatment.
Grouping
Sputum proteomics using label-free LC/MS
N=60 bronchiectasis patients (30 mild, 30 severe by BSI)
![Page 26: Bronchiectasis in non cystic fibrosis patients](https://reader030.fdocuments.net/reader030/viewer/2022020620/61e581c46059ad0d07778e8b/html5/thumbnails/26.jpg)
Better understanding of the natural history of bronchiectasis
Understanding the impact of disease phenotypes
Promote a higher profile for bronchiectasis research
Facilitate Clinical Trials
What EMBARC needs to achieve
![Page 27: Bronchiectasis in non cystic fibrosis patients](https://reader030.fdocuments.net/reader030/viewer/2022020620/61e581c46059ad0d07778e8b/html5/thumbnails/27.jpg)
Novel specific anti-pseudomonals
Neutrophil elastase inhibitors
Inhaled amikacin
Inhaled Colistin
Inhaled ciprofloxacin
Statins
CXCR2 antagonists
CFTR specific therapies
Mannitol
Pulmonary epithelium Airway neutrophil
P. aeruginosa
Circulating neutrophils
H.influenzae
Current Clinical Trials
![Page 28: Bronchiectasis in non cystic fibrosis patients](https://reader030.fdocuments.net/reader030/viewer/2022020620/61e581c46059ad0d07778e8b/html5/thumbnails/28.jpg)
PROMIS study- Inhaled Colistin
Haworth AJRCCM 2014
Underpowered due to•Recruitment target cut from 260 to 144 following recruitment problems•Placebo group had nearly 50% fewer exacerbations than expected
![Page 29: Bronchiectasis in non cystic fibrosis patients](https://reader030.fdocuments.net/reader030/viewer/2022020620/61e581c46059ad0d07778e8b/html5/thumbnails/29.jpg)
Nebulised Aztreonam
Barker Lancet Respir Med 2014
![Page 30: Bronchiectasis in non cystic fibrosis patients](https://reader030.fdocuments.net/reader030/viewer/2022020620/61e581c46059ad0d07778e8b/html5/thumbnails/30.jpg)
Nebulised Aztreonam
Barker Lancet Respir Med 2014
![Page 31: Bronchiectasis in non cystic fibrosis patients](https://reader030.fdocuments.net/reader030/viewer/2022020620/61e581c46059ad0d07778e8b/html5/thumbnails/31.jpg)
Dry powder Mannitol- Discordent results from CF
Missed primary end-pointSmall improvement in QoL
N=233 N=228
![Page 32: Bronchiectasis in non cystic fibrosis patients](https://reader030.fdocuments.net/reader030/viewer/2022020620/61e581c46059ad0d07778e8b/html5/thumbnails/32.jpg)
Registries can help with Clinical Trials
FeasibilityRepresentativenessHealth economics
N=1630
![Page 33: Bronchiectasis in non cystic fibrosis patients](https://reader030.fdocuments.net/reader030/viewer/2022020620/61e581c46059ad0d07778e8b/html5/thumbnails/33.jpg)
![Page 34: Bronchiectasis in non cystic fibrosis patients](https://reader030.fdocuments.net/reader030/viewer/2022020620/61e581c46059ad0d07778e8b/html5/thumbnails/34.jpg)
Summary- Why take part in bronchiectasis research
• Common
• Disabling
• Neglected
• Tractable
![Page 35: Bronchiectasis in non cystic fibrosis patients](https://reader030.fdocuments.net/reader030/viewer/2022020620/61e581c46059ad0d07778e8b/html5/thumbnails/35.jpg)
Chalmers J et al. ERJ in press
![Page 36: Bronchiectasis in non cystic fibrosis patients](https://reader030.fdocuments.net/reader030/viewer/2022020620/61e581c46059ad0d07778e8b/html5/thumbnails/36.jpg)
AcknowledgementsExecutive committee Stefano AlibertiEva Polverino
Scientific CommitteeAnthony De SoyzaFelix RingshausenMarlene MurrisMontserrat VendrellWim BoersmaStefano Aliberti
Steering CommitteeFrancesco BlasiAntoni TorresTobias WelteDiana BiltonRobert WilsonCharles HaworthGernot Rohde Michael LoebingerKaterina DimakouStuart Elborn
www.bronchiectasis.eu
![Page 37: Bronchiectasis in non cystic fibrosis patients](https://reader030.fdocuments.net/reader030/viewer/2022020620/61e581c46059ad0d07778e8b/html5/thumbnails/37.jpg)